Ardelyx Inc
ARDXHealthcare|Biotechnology|USA
$5.28
-0.10 (-1.77%)
Tangible Book
$0.60
Clinical Trials (32)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06810167 Assessing Tenapanor as a Treatment of CF-related Constipation. | Cystic Fibrosis, Constipation | P3 | Recruiting | 25 | Open-label | Tenapanor |
| NCT07382167 A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults | Chronic Idiopathic Constipation (CIC) | P3 | Recruiting | 692 | RCT, Double-blind | Tenapanor 5 mg BID, Tenapanor 25 mg BID, Tenapanor 50 mg BID, Placebo |
| NCT05643534 Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years | Irritable Bowel Syndrome With Constipation (IBS-C) | P3 | Active | 180 | RCT, Double-blind | Tenapanor 50 MG, Tenapanor 25 mg bid, Placebo |
| NCT06553547 4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs | Irritable Bowel Syndrome With Constipation (IBS-C) | P2 | Active | 72 | RCT, Double-blind | Tenapanor, Placebo |
| NCT06460038 Tenapanor in Synucleinopathy-Related Constipation | Synucleinopathy, Parkinson's Disease | P2 | Recruiting | 30 | RCT, Double-blind | Tenapanor, Placebo |
| NCT03988920 A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP | Hyperphosphatemia, End Stage Renal Disease | P4 | Completed | 172 | Open-label | Tenapanor, Sevelamer Carbonate |
| NCT04549597 Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of Hyperphosphatemia | Chronic Kidney Disease Requiring Chronic Dialysis, Hyperphosphatemia | P4 | Completed | 333 | RCT, Open-label | Tenapanor |
| NCT05995899 Effect of Tenapanor on the Metagenomics and Metabolomics of Patients With Irritable Bowel Syndrome With Constipation | IBS, IBS - Irritable Bowel Syndrome | P4 | Completed | 36 | Open-label | Tenapanor |
| NCT03824587 Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy | Hyperphosphatemia | P2P3 | Completed | 236 | RCT, Double-blind | Tenapanor, Placebo, Phosphate Binder Agents |
| NCT02727751 A Long-Term Safety Study of Tenapanor for the Treatment of IBS-C | Constipation Predominant Irritable Bowel Syndrome | P3 | Completed | 312 | Open-label | Tenapanor |
| NCT01923428 The Efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C) | Constipation Predominant Irritable Bowel Syndrome | P2P3 | Completed | 356 | RCT, Double-blind | AZD1722, Placebo |
| NCT03427125 A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis | Hyperphosphatemia | P3 | Completed | 1,559 | RCT, Double-blind | Tenapanor, Placebo, Sevelamer Carbonate |
| NCT02686138 A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C | Constipation Predominant Irritable Bowel Syndrome | P3 | Completed | 593 | RCT, Double-blind | Tenapanor, Placebo |
| NCT02675998 An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD) | Hyperphosphatemia | P3 | Completed | 219 | RCT, Double-blind | Tenapanor, Placebo |
| NCT05905926 Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-C | Irritable Bowel Syndrome With Constipation (IBS-C) | P3 | By Invite | 150 | Open-label | Tenapanor |
| NCT02621892 A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C | Constipation Predominant Irritable Bowel Syndrome | P3 | Completed | 606 | RCT, Double-blind | Tenapanor, Placebo |
| NCT02081534 Dose Finding Study to Treat High Phosphate Levels in the Blood. | Hyperphosphatemia | P2 | Completed | 162 | RCT, Double-blind | AZD1722, Placebo |
| NCT03018067 A Study Evaluating the Onset-of-Action, Safety, and Efficacy of RDX227675 for the Treatment of Hyperkalemia | Hyperkalemia | P2 | Terminated | 60 | RCT, Single-blind | RDX227675, Placebo |
| NCT04780841 A Study Evaluating the Safety and Efficacy of RDX013 for the Treatment of Hyperkalemia | Hyperkalemia | P2 | Completed | 109 | RCT, Single-blind | RDX013, Placebo |
| NCT01847092 A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria | Chronic Kidney Disease, Type 2 Diabetes Mellitus | P2 | Completed | 154 | RCT, Double-blind | AZD1722, Placebo |
| NCT01764854 Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis | End Stage Renal Disease, Chronic Kidney Disease Stage 5 | P2 | Completed | 88 | RCT, Double-blind | AZD1722 (in-patient), Placebo (in-patient), AZD1722 (out-patient), Placebo |
| NCT01340053 A Study to Evaluate the Safety and Efficacy of RDX5791 for the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS-C) | Constipation Predominant Irritable Bowel Syndrome | P2 | Completed | 186 | RCT, Double-blind | RDX5791 |
| NCT02249936 A Phase 1 Study to Examine the Pharmacodynamics of Different AZD1722 Formulations | Healthy | P1 | Completed | 18 | RCT, Double-blind | AZD1722, Omeprazole |
| NCT06203444 An Open-label Study to Evaluate the Pharmacokinetics of Oral Tenapanor in Breast Milk of Lactating Females | Lactation | P1 | Completed | 7 | Open-label | Tenapanor |
| NCT02176252 Safety, Tolerability, Pharmacokinetics and Pharmacodynamic of AZD1722 in Healthy Male and Female Japanese Subjects | Healthy Volunteer | P1 | Completed | 83 | Double-blind | AZD1722, Placebo |
| NCT02140268 To Evaluate the Effect of AZD1722 on the Pharmacokinetics of Oral Midazolam in Healthy Volunteers | Healthy Volunteers | P1 | Completed | 65 | Open-label | Midazolam, AZD1722, AZD1722 and Midazolam |
| NCT02796131 Safety, Tolerability, and Pharmacodynamics of RDX5791 in Healthy Volunteers | Healthy | P1 | Completed | 105 | RCT, Double-blind | RDX5791, Placebo |
| NCT02346890 A Phase 1 Study to Examine the Effect of Renvela on the Pharmacodynamics of AZD1722 | Healthy | P1 | Completed | 16 | RCT, Open-label | AZD1722, Renvela |
| NCT02226783 D5611C00003 - Food Interaction Study With AZD1722 Tablet in Healthy Subjects | Healthy Volunteers Food Interaction Study | P1 | Completed | 37 | RCT, Open-label | AZD1722 salt tablet, AZD1722 free base tablet, AZD1722 free base tablet + Omeprazole |
| NCT02819687 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RDX5791 in Healthy Volunteers | Healthy | P1 | Completed | 80 | Double-blind | RDX5791, Placebo |
| NCT02063386 AZD1722 Open Label, Absorption Distribution Metabolism and Excretion Study | Healthy Volunteers | P1 | Completed | 26 | Open-label | AZD1722 |
| NCT02140281 To Assess the Effect of AZD1722 on the Pharmacokinetics of Cefadroxil in Healthy Volunteers | Healthy Volunteers | P1 | Completed | 71 | RCT, Open-label | Treatment A (cefadroxil alone), Treatment B - AZD1722 followed by cefadroxil |